New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Jo-Ann See

Dr Jo-Ann See

Management of Acne in Teens

Dr Robert Hungerford

Dr Robert Hungerford

An Update on Heart Failure in General Practice

A/Prof Daryl Cheng

A/Prof Daryl Cheng

Invasive Pneumococcal Disease – What GPs Need to Know

A/Prof Yvonne Zissiadis

A/Prof Yvonne Zissiadis

Innovations in Breast Radiation

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970